Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Theravance Biopharma, Inc. made materially false and/or misleading statements and/or failed to disclose that: On the Q3 2025 earnings call (November 10, 2025), CEO Rick Winningham stated the Company was "on track to achieve near-term milestones totaling $75 million in the fourth quarter -- $50 million for Trelegy and $25 million for YUPELRI." On the Q2 2025 call (August 12, 2025), CFO Aziz Sawaf reaffirmed "all elements of our 2025 financial guidance." Neither statement addressed the possibility that a CYPRESS failure could trigger an accelerated strategic review, restructuring costs, or a fundamental reassessment of the Company's development-stage spending. On March 3, 2026, Theravance disclosed that the CYPRESS trial failed to meet its primary endpoint and announced an accelerated strategic review, including termination of the ampreloxetine program. The stock fell approximately 26% in a single session.
In order to be eligible to join the TBPH class action lawsuit, you must have incurred a loss on shares of Theravance Biopharma, Inc. purchased during the class period listed above.
TOP
